The importance of patient-reported outcomes in clinical trials and strategies for future optimization
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Patient-reported outcomes (PROs) can be included in clinical trials as primary or secondary endpoints and are increasingly recognized by regulators, clinicians, and patients as valuable tools to collect patient-centered data. PROs provide unique information on the impact of a medical condition and its treatment from the patient's perspective; therefore, PROs can be included in clinical trials to ensure the impact of a trial intervention is comprehensively assessed. This review first discusses examples of how PRO endpoints have added value to clinical trial interpretation. Second, it describes the problems with current practices in designing, implementing, and reporting PRO studies, and how these problems may be addressed by complying with guidance for protocol development, selecting appropriate PRO measures to match clinically motivated PRO hypotheses, minimizing the rates of avoidable missing PRO data, analyzing and interpreting PRO data, and transparently reporting PRO findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The weaRAble-PRO study administered a selection of validated PRO measures for RA in complement to bespoke digital PRO assessments—that are validated in clinical trials”
From Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000251 · Cited by 2,296
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580 · cited 2×
“21,22 The PRO endpoints led to regulatory approval of mitoxantrone for this indication and wide implementation in the clinic.”
InfluentialSelf-citationReporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension
Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & CONSORT PRO Group, F. T. (2013) · JAMA · doi:10.1001/jama.2013.879 · Cited by 1,386 · cited 2×
“This work informed the development of a CONSORT-PRO Extension (Consolidated Standards of Reporting Trials), which can be considered the minimum reporting items for PRO endpoints (primary or key secondary) in RCTs. 73 CONSORT-PRO consists of 14 items, five of which were newly developed PRO-specific reporting recommenda…”
Self-citationReducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319 · cited 1×
“However, the issue of non-reporting of PROs is emerging and requires attention, as it is unethical to waste the funding, resources, and patients’ efforts expended in PRO data collection.(71)”
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · cited 2×
“In oncology, for example, the American Society of Clinical Oncology (ASCO)(10) and European Society for Medical Oncology (ESMO)(11) have proposed standardized approaches to evaluate clinical trial results by using scores to evaluate the Magnitude of Clinical Benefit (ESMO MCB) or the Net Health Benefit (ASCO), which i…”
Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A.-W., King, M. T., and the SPIRIT-PRO Group, Hunn, A., Bottomley, A., Regnault, A., et al. (2018) · JAMA · doi:10.1001/jama.2017.21903 · Cited by 814 · cited 5×
“A second review examined the PRO content of 26 protocols of Phase III international, ovarian cancer trials published between 2000 and 2016 against a list of PRO-specific items that would eventually inform the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-PRO Extension.(29,30) Of the 26 tr…”
InfluentialSelf-citation
Research works printed but not linked: 2
- [15]Food and Drug Administration Ovarian Cancer Endpoints Workshop April 26, 2006, Meeting Summary 2006 Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Developmen-tResources/CancerDrugs/ucm094598.pdf accessed 09 August 2016 https://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm120657.pdf Accessed 14 August 2017.v
- [56]Mercieca-Bebber R Palmer MJ Brundage M Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review BMJ Open 2016 6 6 e010938 PMC4916640 27311907
Cited by
Items 101–200 of 660
Accumulation of house-dust mite (Der-p-1) levels on mattress covers.
Jooma, O. F., Weinberg, E. G., Berman, D. M., Manjra, A. I., & Potter, P. C. (1995) · PubMed · Cited by 20
Voices that matter: The impact of patient-reported outcome measures on clinical decision-making
Jeyaraman, N., Jeyaraman, M., Ramasubramanian, S., Balaji, S., & Muthu, S. (2024) · World Journal of Methodology · doi:10.5662/wjm.v15.i2.98066 · Cited by 19
Roberts, C., Armson, B., Bartram, D. J., Belshaw, Z., Capon, H., Cherry, G., Villeta, L. C. G., McIntyre, S. L., Odeyemi, I. A. O., & Cook, A. J. C. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.741864 · Cited by 23
“This may be performed using a patient-reported outcome measure (PROM), an instrument that allows the patient to report on aspects of their own health, such as pain and QOL (17, 18).”
MethodNagendrababu, V., Vinothkumar, T. S., Rossi‐Fedele, G., Doğramacı, E. J., Duncan, H. F., Abbott, P. V., Levin, L., Lin, S., & Dummer, P. M. H. (2023) · Dental Traumatology · doi:10.1111/edt.12827 · Cited by 26
Spampinato, S., Tanderup, K., Barcellini, A., Burchardt, E., Eminowicz, G., Šegedin, B., Stankiewicz, M. A., Valgma, M., & Kirchheiner, K. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.110881 · Cited by 24
Heslop, H. E., Stadtmauer, E. A., Levine, J. E., Ballen, K. K., Chen, Y., Dezern, A. E., Eapen, M., Hamadani, M., Hamilton, B. K., Hari, P., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.08.016 · Cited by 20
Patient reported outcomes in the daily practice in clinical oncology: A systematic review
Lutz, A. T., Griza, A., Machado, G. M., Loose, U., Dahmer, A., & Herbert, J. S. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103658 · Cited by 24
Simpson, E. L., Wollenberg, A., Soong, W., Steffensen, L. A., Kurbasic, A., Schneider, S. K. R., Zoidis, J., & Silverberg, J. I. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.07.007 · Cited by 18
Evidence from clinical trials on high-risk medical devices in children: a scoping review
Guerlich, K., Patro-Gołąb, B., Dworakowski, P., Fraser, A. G., Kammermeier, M., Melvin, T., & Koletzko, B. V. (2023) · Pediatric Research · doi:10.1038/s41390-023-02819-4 · Cited by 17
“…in the review conduct concerned determination of device class, complicated by the different device classi fi cation systems (e.g., FDA vs. EU criteria for high-risk medical devices), changes in classi fi cation over time, or no central source of information regarding device class in Europe.”
Marzorati, C., Monzani, D., Mazzocco, K., Pavan, F., Monturano, M., & Pravettoni, G. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.02147 · Cited by 20
Mountain Hiking vs. Forest Therapy: A Study Protocol of Novel Types of Nature-Based Intervention
Pichler, C., Freidl, J., Bischof, M., Kiem, M., Weisböck-Erdheim, R., Huber, D., Squarra, G., Murschetz, P. C., & Hartl, A. J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19073888 · Cited by 26
“Moreover, it points to the demand for a stronger integration of patient-reported outcomes in clinical trials [70].”
BackgroundHabaka, M., Daly, G. R., Shinyanbola, D., Alabdulrahman, M., McGrath, J., Dowling, G. P., Hehir, C. M., Huang, H. Y. R., Hill, A. D. K., Varešlija, D., et al. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01669-z · Cited by 17
“One effective way of measuring quality of life impacts during clinical trials is through patient reported outcomes, as it allows a holistic and varied assessment of the treatment regimen [105].”
Chan, S. W. W., Chien, C., Wong, A. Y. L., & Pang, M. Y. C. (2021) · Quality of Life Research · doi:10.1007/s11136-021-02759-8 · Cited by 18
Ellis, G. K., Chapman, H., Manda, A., Salima, A., Itimu, S., Banda, G., Séguin, R., Manda, G. E., Butia, M., Huibers, M. H. W., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29257 · Cited by 18
Social media mining in drug development—Fundamentals and use cases
Koss, J., Rheinlaender, A., Truebel, H., & Bohnet-Joschko, S. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.012 · Cited by 17
Eliya, Y., Averbuch, T., Le, N., Xie, F., Thabane, L., Mamas, M. A., & Spall, H. G. C. V. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022353 · Cited by 19
Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROM
Müller, A. R., Luijten, M. A. J., Haverman, L., de Ranitz‐Greven, W. L., Janssens, P., Rietman, A. B., ten Hoopen, L. W., de Graaff, L. C. G., de Wit, M. Y., Jansen, A., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03012-4 · Cited by 21
Patient-Reported Outcomes in Clinical Trials: From an Endpoint to an Intervention in Cancer Care
Narra, L. R., Verdini, N. P., Lapen, K., Nipp, R. D., & Gillespie, E. F. (2023) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.07.002 · Cited by 21
Baalmann, A.-K., Blome, C., Stoletzki, N., Donhauser, T., Apfelbacher, C., & Piontek, K. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084202 · Cited by 22
“14 For PCC, disease-specific PROMs have been developed to assess symptoms and symptom burden, 15 16 as well as the impact of the condition on activities of daily living 15 and HRQoL.”
Emad-Eldin, M., Balata, G. F., el-Shorbagy, E., Hamed, M. S., & Attia, M. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.828 · Cited by 31
Cheung, D. S. T., Chau, P. H., Yeung, W., Deng, W., Hong, A. W. L., & Tiwari, A. (2021) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.9102 · Cited by 18
Influence of compression garments on proprioception: A systematic review and meta‐analysis
Ghai, S., Nilson, F., Gustavsson, J., & Ghai, I. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15144 · Cited by 18
Nikolovski, J., Kim, B., Morton, R. L., Mercieca‐Bebber, R., Lévesque, J., Tinsley, M., Sutherland, K., Rossiter, B., Fagan, M., Hartas, G., et al. (2025) · Quality of Life Research · doi:10.1007/s11136-025-03913-2 · Cited by 21
“Patient-reported outcome measures (PROMs) enable the collection of self-reported information from patients about their health condition without interpretation from anyone else [19] and assess outcomes such as disease symptoms, treatment side-effects, and HRQL [ 20, 21].”
Self-citationCheung, W. Y., Kavan, P., & Dolley, A. (2020) · Current Oncology · doi:10.3747/co.27.6533 · Cited by 16
Lassaletta, L., Calvino, M., Cuadrado, I. P. S., Skarzynski, P. H., Cywka, K. B., Czajka, N., Kutyba, J. J., Távora‐Vieira, D., de Heyning, P. V., Mertens, G., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19052503 · Cited by 16
Shukla, P., Huang, L., Zhao, A. H., Sharew, B., Miller, B., Beffa, L., Petro, C. C., Krpata, D. M., Prabhu, A. S., & Rosen, M. J. (2023) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000754 · Cited by 15
Jannati, N., Salehinejad, S., Kuenzig, M. E., & Peña-Sánchez, J. N. (2023) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2023.105249 · Cited by 14
Dhabalia, R., Kashikar, S. V., Parihar, P. H., & Mishra, G. (2024) · Cureus · doi:10.7759/cureus.54808 · Cited by 33
“This research-driven approach is instrumental in advancing the field of neurology and improving patient care [11].”
BackgroundHall, R., Trennery, C., Chan, R. H., Gater, A., Bradley, H., Sikirica, M. V., von Maltzahn, R., Sousa, A. R., & Nelsen, L. M. (2020) · Value in Health · doi:10.1016/j.jval.2019.11.005 · Cited by 16
Chen, M., Lin, C., Rosenthal, L. S., Opal, P., & Kuo, S. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117417 · Cited by 16
Liss, A., Wennström, J. L., Welander, M., Tomasi, C., Petzold, M., & Abrahamsson, K. H. (2021) · BMC Oral Health · doi:10.1186/s12903-021-02001-4 · Cited by 20
“To include patient-reported outcome (PRO) measures in clinical trials, as a complement to “objective” clinical observations, are essential in order to evaluate the quality of care and to bring knowledge of importance to improve the quality of care [15, 16].”
Gos, E., Sagan, A., Skarzynski, P. H., & Skarżyńśki, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237778 · Cited by 27
“In clinical trials they serve as primary or secondary endpoints [4], and they are used in health systems and in health policymaking for assessing and improving quality of care [5, 6].”
BackgroundPuccini, A., Viscardi, G., Ciani, O., Efficace, F., Piattelli, A., Beretta, G. D., Petruzzelli, D., Popoli, P., Lorenzo, F. D., Longo, F., et al. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000783 · Cited by 26
“41 As the landscape of clinical research continues to evolve, ongoing dialogue and innovation will be necessary to improve the utility of PROs and ultimately improve patient-centred care.”
Patient‐reported Outcomes (PROs) in clinical trials in paediatric dentistry
Gilchrist, F., & Marshman, Z. (2020) · International Journal of Paediatric Dentistry · doi:10.1111/ipd.12768 · Cited by 16
Outcomes in Facial Feminization Surgery: A Systematic Review
Uhlman, K., Gormley, J., Churchill, I. F., Huynh, M., Leveille, C. F., McRae, M. H., McRae, M. C., & Musgrave, M. A. (2022) · Facial Plastic Surgery & Aesthetic Medicine · doi:10.1089/fpsam.2021.0293 · Cited by 14
“34 This can be especially important when studying interventions such as FFS.”
Tam, C. S. L., Lamanna, N., O'Brien, S. M., Qiu, L., Yang, K., Barnes, G., Wu, K., Salmi, T., & Brown, J. R. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2262378 · Cited by 14
“Patient-reported outcomes (PROs) have long been recognized as important tools in evaluating drugs in clinical trials, particularly the positive effects of treatment and the negative effects of treatment-related AEs on HRQoL 5 .”
BackgroundMoss, C. L., Aggarwal, A. K., Qureshi, A., Taylor, B. P., Urbano, T. G., & Hemelrijck, M. V. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01648-x · Cited by 16
de Wolff, M. G., Midtgaard, J., Johansen, M., Rom, A. L., Rosthøj, S., Tabor, A., & Hegaard, H. K. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18157875 · Cited by 14
“We used validated psychometric tools to measure the patient-reported outcomes [57].”
MethodDesign a Clinical Research Protocol: Influence of Real-World Setting
Cimino, J., & Braun, C. (2023) · Healthcare · doi:10.3390/healthcare11162254 · Cited by 18
Neoadjuvant and adjuvant end-points in health technology assessment in oncology
Harbeck, N., Schneeweiß, A., Thuss-Patience, P. C., Miller, K., Garbe, C., Griesinger, F., Eberhardt, W., Klußmann, J. P., Wollenberg, B., Grimm, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.006 · Cited by 14
Gonzalez, A., Nguyen, U.-S. D. T., Franklin, P., Baréa, C., Hannouche, D., & Lübbeke, A. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05004-6 · Cited by 11
“PROs have gained much importance in health care evaluation, health technology assessment and quality improvement, and are increasingly used in clinical studies of medical devices [1, 2].”
BackgroundPiontek, K., Donhauser, T., Kann, G., Fechtner, M., Apfelbacher, C., & Gabes, M. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03358-5 · Cited by 15
“PROMs can be used to measure the impact of an intervention including disease symptoms or treatment side effects, functional outcomes such as physical, emotional and social functioning, or multidimensional constructs such as healthrelated quality of life (HRQoL) [11].”
BackgroundCapturing Patient Voice to Improve Outcomes That Matter to Patients with Desmoid Tumor
Kasper, B., Gounder, M. M., Hernandez, L., Baumgarten, C., & Ratan, R. (2024) · Cancer Management and Research · doi:10.2147/cmar.s362694 · Cited by 13
“27 Importantly, their use in clinical trials has increased over time.”
BackgroundMarion, S., Ghazal, L. V., Roth, T. M., Shanahan, K., Thom, B., & Chino, F. L. (2024) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2024.07.001 · Cited by 19
Hunter, T. M., Cao, D., Zhang, X. M., Xavier, N., Poon, J. L., & Fitch, A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01723-w · Cited by 20
“Patient-reported outcomes (PROs) that measure HRQoL capture the patients’ perspectives on their health and well-being and provide valuable insights into their day-to-day functioning that can inform treatment-related decisions [26, 27].”
Sherif, M. A., Anter, E., Graetz, C., & El‐Sayed, K. M. F. (2025) · BMC Oral Health · doi:10.1186/s12903-025-06115-x · Cited by 22
“Finally, as an increasing interest exists in recording patient centered outcomes in clinical trials [76], in accordance with an earlier investigation [46] patient reported pain scores were monitored for the second and third day using the VAS scores.”
Kremer, M., Alferink, J., Wynsma, S. M., Shirk, T., & Ledonio, C. G. T. (2019) · Journal of Spine Surgery · doi:10.21037/jss.2019.06.07 · Cited by 13
“However, patient-reported outcome measures are recognized (such as ODI and VAS pain scores) as the most appropriate instruments to assess the effectiveness of healthcare interventions from the patient’s perspective, and are sometimes used as metrics for healthcare delivery performance (14,15).”
BackgroundPatient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy
Johnson, H. M., Lin, H. Y., Shen, Y., Diego, E. J. B., Krishnamurthy, S., Yang, W. T., Smith, B. D., Valero, V., Lucci, A., Sun, S. X., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.33933 · Cited by 14
Parewa, M., Burman, A. S., Brahma, A., Rutten, L., Sadhukhan, S., Misra, P., Gupta, B., Saklani, N. K., Michael, J., Basu, A., et al. (2021) · Complementary Medicine Research · doi:10.1159/000514524 · Cited by 20
Barriers and Best Practices for the Use of Patient-Reported Outcome Measures in Emergency Medicine
Lin, M., Kligler, S. K., Friedman, B. W., Kim, H. S., Rising, K. L., Samuels‐Kalow, M. E., & Eucker, S. A. (2023) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2022.12.017 · Cited by 16
Thase, M. E., Ismail, Z., Meehan, S. R., Weiss, C., Régnier, S. A., Larsen, K. G., & McIntyre, R. S. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.02.008 · Cited by 13
Jang, S., Lee, B., Lee, E., Kim, J., Lee, J. I., Lim, J., Hwang, J. H., & Jang, S. (2023) · Journal of Pain Research · doi:10.2147/jpr.s388757 · Cited by 21
Robotic total knee arthroplasty safely reduces length of stay in an Asian public healthcare system
Chan, K. C. A., Cheung, A., Ping Keung, C. H. A. N., Luk, M. H., Chiu, P., & Fu, H. (2025) · Bone & Joint Open · doi:10.1302/2633-1462.61.bjo-2024-0184.r1 · Cited by 12
Wang, M., & Reeve, B. B. (2021) · Statistical Methods in Medical Research · doi:10.1177/09622802211043263 · Cited by 12
“In the past two decades, the importance of patient-reported outcomes (PROs) has been well recognized in the medical and healthcare research community, and an increasing number of clinical trials have included endpoints utilizing PRO instruments.(1,2) Typically, a PRO instrument consists of multiple survey questions th…”
BackgroundLapin, B. R., Garey, K. W., Wu, H., Pham, S. V., Huang, S. P., Reese, P. R., Wang, E., & Deshpande, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac554 · Cited by 13
Kristeleit, R. S., Mathews, C. A., Redondo, A., Boklage, S., Hanlon, J. T., Im, E., & Brown, J. (2022) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003492 · Cited by 14
Hetherington, K., Wakefield, C. E., Kunalan, K. P. K., Donoghoe, M. W., McGill, B. C., Fardell, J. E., Daly, R., Deyell, R. J., & Ziegler, D. S. (2022) · Cancers · doi:10.3390/cancers14215310 · Cited by 14
Holmes, J. M., Hercinovic, A., Melia, B. M., Leske, D. A., Hatt, S. R., Chandler, D. L., Dean, T. W., Kraker, R. T., Enyedi, L. B., Wallace, D. K., et al. (2021) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2020.11.021 · Cited by 12
Lin, C., Sajeev, G., Stiff, P. J., Brunstein, C. G., Cutler, C. S., Sanz, G. F., Lindemans, C. A., Rezvani, A. R., Hanna, R., Koh, L. P., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.09.018 · Cited by 12
Age Significantly Affects Response Rate to Outcomes Questionnaires Using Mobile Messaging Software
Jildeh, T. R., Castle, J. P., Abbas, M. J., Dash, M. E., Akioyamen, N. O., & Okoroha, K. R. (2021) · Arthroscopy Sports Medicine and Rehabilitation · doi:10.1016/j.asmr.2021.06.004 · Cited by 13
“Arthroscopy, Sports Medicine, and Rehabilitation, V function.(2,3) Although the use and value of PROs has increased in recent years, there has been a lack of consensus regarding the optimal logistics and use within clinical practice.”
BackgroundTawfik, B., Dayao, Z. R., Brown-Glaberman, U. A., Pankratz, V. S., Lafky, J. M., Loprinzi, C. L., & Barton, D. L. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-08082-x · Cited by 11
“We believe patient-reported outcomes are the ideal measurement tool for the measurement of neuropathy as it directly collects the patient’s perspective [37].”
BackgroundPulmonary Function and Lung Fibrosis up to 12 Years After Breast Cancer Radiotherapy
Karlsen, J., Tandstad, T., Steinshamn, S., Salvesen, Ø. O., Parlikar, N., Lundgren, S., & Reidunsdatter, R. J. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.10.026 · Cited by 12
Patient-reported outcomes of zirconia dental implants: a systematic review and future directions
Arefnia, B., Fakheran, O., Jakse, N., & Payer, M. (2025) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-025-00839-8 · Cited by 17
“The oral health-related quality of life (OHRQoL) and other psychosocial outcomes of interventions should be considered as essential supplements in clinical trials [20–23].”
Schade, A. T., Nyamulani, N., Banza, L. N., Metcalfe, A. J., Leather, A. J. M., Madan, J., Lallloo, D. G., Harrison, W. J., & MacPherson, P. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17145.1 · Cited by 12
Murea, M., Highland, B. R., Yang, W. Z., Dressler, E. V. M., & Russell, G. B. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02946-w · Cited by 11
“Clinical trials are increasingly analyzing patient’s perspectives on treatment-related physical, functional and psychological impact [28].”
BackgroundTherrien, F., Meehan, S. R., Weiss, C., Dine, J. L., Brown, T. M., & MacKenzie, E. M. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00517-z · Cited by 11
Health resources for South Africa: A scoping review
Pascoe, M., Mahura, O., & Dean, J. (2020) · Health SA Gesondheid · doi:10.4102/hsag.v25i0.1378 · Cited by 14
“in quality of life as an outcome measure (Mercieca-Bebber et al. 2018).”
BackgroundSanchez, L. J., Leleu, X. P., Beaumont, J. L., Yu, H., Hudgens, S. A., Simonova, M., Auner, H. W., Quach, H., Delimpasi, S., Špıčka, I., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26282 · Cited by 11
“has become an important component in clinical trials as they provide information on the impact of a disease and treatment from the patient's perspective.(6) To this end, analyses of PROs were included in the BOSTON trial to evaluate patterns in therapy-induced PN symptoms, pain, and function.”
MethodBothorel, H., Pernoud, A., & Christofilopoulos, P. (2024) · Patient Related Outcome Measures · doi:10.2147/prom.s439707 · Cited by 10
Doza, G. L., Heden, S. V., Felix, F. O., Singh, V., & Beaudart, C. (2024) · The Journal of Frailty & Aging · doi:10.14283/jfa.2024.47 · Cited by 10
“PROMs and PREMs aim to report on diseases and symptoms, treatment side effects (such as pain, fatigue, or anxiety), functional outcomes (physical, sexual, social, role, emotional, or cognitive functioning), or multidimensional constructs like HRQoL or health utility (6).”
Teferi, M., Staniford, L. J., Connell, S., Das‐Gupta, Z., DeSilva, U., Saoud, Y., Miller, I., Mohan, M., Nienhuijs, S. W., Poddar, M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103422 · Cited by 16
“27 The value of including PROMs is well recognized by regulators, clinicians, and patients to allow the consideration of the patient perspective 27 also highlighted the need to select appropriate PROMs to capture the patient perspective and allow transparent reporting of PROMs.”
Silva, W. S., Grove, C. R., Gerend, P. L., Ryan, C., & Schubert, M. C. (2022) · Journal of Vestibular Research · doi:10.3233/ves-220022 · Cited by 10
Saygın, D., Kim, H., Douglas, C. E., Erman, B., Wilkerson, J., McGrath, J. A., Oddis, C. V., Lundberg, I. E., Amato, A. A., Torre, I. G.-D. L., et al. (2023) · Lara D. Veeken · doi:10.1093/rheumatology/kead110 · Cited by 10
Rao, C., Lascio, E. D., Demanse, D., Marshall, N. J., Sopala, M., & Luca, V. D. (2023) · Frontiers in Digital Health · doi:10.3389/fdgth.2023.1099456 · Cited by 12
Citrome, L., Mychaskiw, M. A., Cortez, A., Opler, M. G. A., Sopina, L., & Kotak, S. V. (2023) · PubMed Central · Cited by 13
Twohig, H., Mitchell, C. A., Mallen, C. D., & Müller, S. (2022) · Rheumatology · doi:10.1093/rheumatology/keac317 · Cited by 10
Bakker, J. P., McClenahan, S. J., Fromy, P., Turner, S., Peterson, B., Vandendriessche, B., & Goldsack, J. C. (2024) · Journal of Medical Internet Research · doi:10.2196/58956 · Cited by 12
Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance
suri, C., Pande, B., Sahithi, L. S., Swarnkar, S., Khelkar, T., & Verma, H. K. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.164 · Cited by 14
Defining a ‘cells to society’ research framework for appendiceal tumours
Holowatyj, A. N., Overman, M. J., Votanopoulos, K. I., Lowy, A. M., Wagner, P., Washington, M. K., Eng, C., Foo, W. C., Goldberg, R. M., Hosseini, M., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00788-2 · Cited by 13
“Incorporation of patient-reported outcome measurement tools in clinical trial design 153 should also be explored to deepen our understanding of individual perspectives related to the health, quality-of-life and functional status of patients 154 .”
Patient-reported outcomes as drivers of postoperative delirium in the postanaesthesia care unit
Berger‐Estilita, J., Marcolino, I., Gisselbaek, M., Seidl, C., Buehrer, T. W., Fortuna, I., Meço, B. C., Radtke, F. M., & Saxena, S. (2025) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002258 · Cited by 9
Ruzich, E., Ritchie, J., Sowell, F. G., Mansur, A., Griffiths, P., Birkett, H., Harman, D., Spink, J., James, D., & Reaney, M. D. (2023) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocad099 · Cited by 8
Dimenäs, S. L., Andersson, J. S., Jönsson, B., Lundgren, J., Petzold, M., Östberg, A., & Abrahamsson, K. H. (2023) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13883 · Cited by 12
Efficace, F., Buckstein, R. J., Abel, G. A., Giesinger, J. M., Fenaux, P., Bewersdorf, J. P., Brunner, A. M., Bejar, R. L., Borate, U., Dezern, A. E., et al. (2024) · HemaSphere · doi:10.1002/hem3.69 · Cited by 9
Current state of developing advanced therapies for rare diseases in the European Union
Qiu, T., Wang, Y., Dabbous, M., Hanna, E., Han, R., Liang, S., & Toumi, M. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1835640 · Cited by 11
Teni, F. S., Rolfson, O., Devlin, N. J., Parkin, D. W., Nauclér, E., Burström, K., & The Swedish Quality Register (SWEQR) Study Group (2021) · JMIR Research Protocols · doi:10.2196/27669 · Cited by 9
Oldenburger, E., Neyens, I., Coolbrandt, A., Isebaert, S. F., Sevenants, A., Audenhove, C. V., & Haustermans, K. M. (2021) · Patient Education and Counseling · doi:10.1016/j.pec.2021.11.022 · Cited by 11
Smeele, H. P., Dijkstra, R. C. H., Kimman, M., van der Hulst, R. R. W. J., & Tuinder, S. M. H. (2022) · Patient · doi:10.1007/s40271-021-00565-5 · Cited by 12
Horta-Baas, G. (2022) · Patient Related Outcome Measures · doi:10.2147/prom.s256715 · Cited by 9
“This study showed that CT-P13 and infliximab have equivalent pharmacokinetic profiles, comparable efficacy and safety, and no clinically important differences in PROMs.”
InfluentialGene Therapy in Hemophilia: A Transformational Patient Experience
Rasul, E., Hallock, R., Hellmann, M., Konduros, J., Pembroke, L., LeCleir, G., Malacan, J., & Mackensen, S. V. (2023) · Journal of Patient Experience · doi:10.1177/23743735231193573 · Cited by 12
“*Domains were rated by each patient based on an index value (1-100) and added for a cumulative score.”
MethodForsbrand, M., Turkiewicz, A., Petersson, I. F., Sennehed, C. P., & Stigmar, K. (2020) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2020.1717081 · Cited by 12
“interventions by adding unique information about patients benefits of an intervention [36].”
BackgroundWeißbuch Citizen Science Strategie 2030 für DeutschlandPreprint
Bonn, A., Brink, W., Hecker, S., Herrmann, T. M., Liedtke, C., Premke-Kraus, M., Voigt‐Heucke, S. L., von Gönner, J., Altmann, C. S., Bauhus, W., et al. (2021) · SocArXiv (OSF Preprints) · doi:10.31235/osf.io/ew4uk_v1 · Cited by 14
Patient-reported outcome measures as an outcome variable in sports medicine research
Valier, A. R. S., Bliven, K. C. H., Lam, K. C., & McLeod, T. C. V. (2022) · Frontiers in Sports and Active Living · doi:10.3389/fspor.2022.1006905 · Cited by 7
“PROMs require training related to the study protocol, purpose of the PROMs, informed consent procedures, and anticipated participant questions to provide firm guidance on executing the study protocol to support participant compliance and the situation of missing or incomplete data (25).”
BackgroundMethodInfluentialIllg, A., Amann, E., Koinig, K. A., Anderson, I., Lenarz, T., & Billinger-Finke, M. (2023) · Frontiers in Audiology and Otology · doi:10.3389/fauot.2023.1207220 · Cited by 9
Isaacs, D. A., Hay, K. R., Hoadley, J., McDonell, K. E., Brown, A. E., Wynn, A., Claassen, D. O., & Gibson, J. S. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106969 · Cited by 8
Patient‐reported outcome measures in pediatrics: An overview of reviews
Lei, R., Xiong, J., Wang, H., Li, Y., Estill, J. A. M., Li, Q., & Chen, Y. (2024) · Pediatric Discovery · doi:10.1002/pdi3.77 · Cited by 8
Durgam, S., Earley, W. R., Kozauer, S. G., Mo, Y., Lakkis, H. D., Edwards, J. B., Kornstein, S. G., & Fava, M. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250292 · Cited by 10
Elevating the role of carers in rheumatoid arthritis management in the Asia‐Pacific region
Pile, K. D., Norager, R., Skillecorn, M., Gibson, K., Elderton, S., Favorito, W., Li, Z., Mu, R., Nakahara, H., Kishimoto, M., et al. (2020) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13893 · Cited by 8
Chumchuen, S., Apivatgaroon, A., Phanichwong, P., Kanokvaleewong, C., Pinsornsak, P., & Pongcharoen, B. (2022) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671221141095 · Cited by 8
“Patient-reported outcome measures are useful for assessing a patient’s health condition.(27) Many such measures were developed to evaluate symptoms and function in patients with hip disorders and assess outcomes after treatment.”
BackgroundSwain, M. G., Pettersson, B., Meyers, O. I., Venerus, M., & Oscarsson, J. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000036 · Cited by 10
“[17] Moreover, data from PROs are important for supporting medication labeling claims, health care policy, and clinical decision-making.[18] PRO instruments can be developed to record and quantify responses from patients.”
Talevski, J., Gianoudis, J., Bailey, C. A., Ebeling, P. R., Nowson, C. A., Hill, K., Sanders, K. M., & Daly, R. M. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06693-y · Cited by 8
“Patient-reported outcomes (PROs) are measurements that come directly from individuals themselves, without interpretation of the response by a clinician or another person, and are increasingly being evaluated in clinical trials [16].”
Background
Metadata
- Authors
- Mercieca-Bebber, R., King, M. T., Calvert, M. J., Stockler, M. R., & Friedlander, M.
- Affiliations
- The University of Sydney (AU)
- National Institute for Health and Care Research (GB)
- Corresponding author
- Friedlander, Michael
- Venue
- Patient Related Outcome Measures
- Publisher
- Informa UK Limited
- Published
- 2018-11
- Volume
- Volume 9
- Pages
- 353-367
- ISSN
- 1179-271X (ISSN-L)
- PMC
- PMC6219423
- OpenAlex
- W2899320385
- Cited by
- 659
- References
- 73
- Citations by year
- 2026: 77 · 2025: 129 · 2024: 138 · 2023: 88 · 2022: 85 · 2021: 75 · 2020: 54 · 2019: 12
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Related Outcome Measures (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- University Hospitals Birmingham NHS Foundation Trust
- Australian Government
- National Institute for Health and Care Research
- University of Birmingham
- Cancer Australia
- Surgical Reconstruction and Microbiology Research Centre
- National Health and Medical Research Council
- Birmingham Biomedical Research Centre
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- patient-reported outcomes, clinical trial endpoints, missing data, protocol design, patient-centered outcomes, regulatory guidelines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.